Chang Sun1, Yi Wang2, Hou Shan Yao3, Zhi Qian Hu4. 1. Department of General Surgery, Shanghai Chang Zheng Hospital, Second Military Medical University, 415 Feng Yang Road, Shanghai 200003, China. Electronic address: sunchangdoc@163.com. 2. Department of General Surgery, Shanghai Chang Zheng Hospital, Second Military Medical University, 415 Feng Yang Road, Shanghai 200003, China. Electronic address: wyirex@sina.com. 3. Department of General Surgery, Shanghai Chang Zheng Hospital, Second Military Medical University, 415 Feng Yang Road, Shanghai 200003, China. Electronic address: yao-hs@hotmail.com. 4. Department of General Surgery, Shanghai Chang Zheng Hospital, Second Military Medical University, 415 Feng Yang Road, Shanghai 200003, China. Electronic address: huzq62@163.com.
Abstract
BACKGROUND: Perioperative allogeneic blood transfusion (ABT) may be a deleterious predictor on the prognosis of gastric cancer (GC) for subjects who had undergone curative surgeries. In this article we proposed to figure out the effect of ABT with a systematic review and meta-analysis. METHODS: Relevant articles were identified by searching Pubmed and Embase to March 2014. A random-effects model or fixed-effects model was used to calculate pooled odds ratios (ORs). Sensitivity analysis, meta-regression, stratified analysis, dose-response meta-analysis were conducted, and publication bias tested. RESULTS: Eighteen studies (9120 GC patients) were included, of which 36.3% received transfusions. ABT was associated with increased all-cause mortality (OR, 2.17; 95% confidence interval [CI], 1.72-2.74; p<0.001; I2=75%). Sensitivity analysis showed significant changes in ORs while meta-regression had little influence on ORs. Galbraith plot revealed the OR reduced to 2.10 (95% CI, 1.86-2.37; p<0.001) with tau2 reduced to 0.00 and I2 reduced to 0%. RESULTS of stratified analysis were robust and consistent. Dose-response meta-analysis revealed that all-cause mortality was significantly lower in patients transfused with ≤800 mL of blood than those transfused with >800 mL (OR, 0.58; 95% CI, 0.37-0.92; p=0.02; I2=54%). ABT was also associated with increased cancer-related mortality (OR, 2.57, p=0.011) and recurrence (OR, 1.52, p=0.017). CONCLUSIONS: In GC patients undergoing curative surgeries, ABTs are associated with a worse prognosis, including all-cause mortality, cancer-related mortality and recurrence. Patient blood management should be investigated further to minimize use of ABT.
BACKGROUND: Perioperative allogeneic blood transfusion (ABT) may be a deleterious predictor on the prognosis of gastric cancer (GC) for subjects who had undergone curative surgeries. In this article we proposed to figure out the effect of ABT with a systematic review and meta-analysis. METHODS: Relevant articles were identified by searching Pubmed and Embase to March 2014. A random-effects model or fixed-effects model was used to calculate pooled odds ratios (ORs). Sensitivity analysis, meta-regression, stratified analysis, dose-response meta-analysis were conducted, and publication bias tested. RESULTS: Eighteen studies (9120 GC patients) were included, of which 36.3% received transfusions. ABT was associated with increased all-cause mortality (OR, 2.17; 95% confidence interval [CI], 1.72-2.74; p<0.001; I2=75%). Sensitivity analysis showed significant changes in ORs while meta-regression had little influence on ORs. Galbraith plot revealed the OR reduced to 2.10 (95% CI, 1.86-2.37; p<0.001) with tau2 reduced to 0.00 and I2 reduced to 0%. RESULTS of stratified analysis were robust and consistent. Dose-response meta-analysis revealed that all-cause mortality was significantly lower in patients transfused with ≤800 mL of blood than those transfused with >800 mL (OR, 0.58; 95% CI, 0.37-0.92; p=0.02; I2=54%). ABT was also associated with increased cancer-related mortality (OR, 2.57, p=0.011) and recurrence (OR, 1.52, p=0.017). CONCLUSIONS: In GC patients undergoing curative surgeries, ABTs are associated with a worse prognosis, including all-cause mortality, cancer-related mortality and recurrence. Patient blood management should be investigated further to minimize use of ABT.
Authors: Lauren M Postlewait; Malcolm H Squires; David A Kooby; Sharon M Weber; Charles R Scoggins; Kenneth Cardona; Clifford S Cho; Robert C G Martin; Emily R Winslow; Shishir K Maithel Journal: HPB (Oxford) Date: 2015-11-14 Impact factor: 3.647
Authors: Caroline E Poorman; Lauren M Postlewait; Cecilia G Ethun; Thuy B Tran; Jason D Prescott; Timothy M Pawlik; Tracy S Wang; Jason Glenn; Ioannis Hatzaras; Rivfka Shenoy; John E Phay; Kara Keplinger; Ryan C Fields; Linda X Jin; Sharon M Weber; Ahmed Salem; Jason K Sicklick; Shady Gad; Adam C Yopp; John C Mansour; Quan-Yang Duh; Natalie Seiser; Carmen C Solorzano; Colleen M Kiernan; Konstantinos I Votanopoulos; Edward A Levine; Charles A Staley; George A Poultsides; Shishir K Maithel Journal: Am Surg Date: 2017-07-01 Impact factor: 0.688
Authors: Paula Marincola Smith; Jordan Baechle; Carmen C Solórzano; Marcus Tan; Alexandra G Lopez-Aguiar; Mary Dillhoff; Eliza Beal; George Poultsides; John G D Cannon; Flavio G Rocha; Angelena Crown; Clifford Cho; Megan Beems; Emily R Winslow; Victoria R Rendell; Bradley A Krasnick; Ryan C Fields; Shishir K Maithel; Christina E Bailey; Kamran Idrees Journal: HPB (Oxford) Date: 2019-12-02 Impact factor: 3.647
Authors: Thomas Frietsch; Andrea U Steinbicker; Audrey Horn; Matthes Metz; Gerald Dietrich; Markus A Weigand; Jonathan H Waters; Dania Fischer Journal: Transfus Med Hemother Date: 2022-05-11 Impact factor: 4.040
Authors: Yuhree Kim; Gaya Spolverato; Donald J Lucas; Aslam Ejaz; Li Xu; Doris Wagner; Steven M Frank; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2015-08-26 Impact factor: 3.452
Authors: Juan P Cata; Cristina Gutierrez; Reza J Mehran; David Rice; Joseph Nates; Lei Feng; Andrea Rodriguez-Restrepo; Fernando Martinez; Gabriel Mena; Vijaya Gottumukkala Journal: Cancer Cell Microenviron Date: 2016
Authors: Lauren S Prescott; Jolyn S Taylor; Maria A Lopez-Olivo; Mark F Munsell; Helena M VonVille; David R Lairson; Diane C Bodurka Journal: Cancer Treat Rev Date: 2016-03-28 Impact factor: 12.111